Evaluation of allopurinol efficacy in patients with nonalcoholic fatty liver disease: a randomized, double blind, placebo-controlled trial

Oroumia University of Medical Sciences0 个研究点目标入组 44 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Age between 18 and 70 years
•Not having history of alcohol consumption
•Lack of other liver diseases
•The levels of aminotransferases should not exceed 2.5 times the upper limit of normal
•No previous allergy to allopurinol
•Not having chronic kidney disease (definedas an estimated glomerular filtration rate <60 mL/min/1.73m2)
•Serum uric acid levels greater than 4 mg/dl for men and more than 3 mg/dl for women
•For diabetic patients, hemoglobin A1c should be less than 8% and the dose of antidiabetic drugs should be constant for at least 3 months
•Not having hematological disorders
•Not having kidney stones

•Pregnancy and lactation
•Use of drugs interact with allopurinol (including didanosine, angiotensin-converting enzyme inhibitors, antacids (except sodium bicarbonate), azathioprine, mercaptopurine, vitamin K antagonists (including warfarin and other coumarin derivatives))
•Taking hepatotoxic drugs (including calcium channel blockers, high doses of synthetic estrogens, methotrexate, amiodarone, chloroquine)
•Occurrence of allergic reaction due to allopurinol intake

发起方

Oroumia University of Medical Sciences